STOCK TITAN

Insider Files Form 144 for IONS — 10,000 Shares Proposed Sale ($503.7K)

Filing Impact
(Low)
Filing Sentiment
(Neutral)
Form Type
144

Rhea-AI Filing Summary

Ionis Pharmaceuticals insider sale notice: This Form 144 shows a proposed sale of 10,000 shares of Ionis common stock through Stifel Nicolaus & Company, with an aggregate market value of $503,671. The filing reports the shares were acquired as restricted stock units on 01/15/2019 (16,802 units originally) and payment was in cash. The filer previously sold 10,000 shares on 08/05/2025 for $428,593. The company has 159,391,229 shares outstanding, so the proposed sale represents approximately 0.0063% of outstanding shares. The filer attests there is no undisclosed material information.

Positive

  • Complete disclosure of broker, quantity, acquisition date, and prior sale within three months
  • Insider attestation asserts no undisclosed material information, aligning with compliance expectations

Negative

  • Insider sale reported (10,000 shares), which some investors monitor as a potential signal despite being small
  • No Rule 10b5-1 plan date provided in the remarks section, so planned-trading status is not stated

Insights

TL;DR: Routine Form 144 filing reporting an insider sale of 10,000 shares valued at $503,671; small relative to outstanding stock.

The filing documents a proposed brokered sale of 10,000 Ionis shares via Stifel Nicolaus with an aggregate market value of $503,671. The securities were acquired as restricted stock units on 01/15/2019 and previously a sale of 10,000 shares occurred on 08/05/2025 for $428,593. Given 159,391,229 shares outstanding, the proposed sale is roughly 0.0063% of the float, which is immaterial from a market-cap perspective. The filing includes the standard insider attestation regarding material nonpublic information.

TL;DR: Filing reflects compliance with Rule 144 disclosure for an insider sale; nothing in the record indicates regulatory or governance concerns.

The notice provides required disclosure elements: broker name and address, quantity, aggregate market value, acquisition date and nature (restricted stock units), and recent sales within three months. The inclusion of the prior sale on 08/05/2025 and the attestation statement supports procedural transparency. There are no statements of plan adoption dates for Rule 10b5-1 in the remarks section.

144: Filer Information

144: Issuer Information

144: Securities Information



Furnish the following information with respect to the acquisition of the securities to be sold and with respect to the payment of all or any part of the purchase price or other consideration therefor:

144: Securities To Be Sold


* If the securities were purchased and full payment therefor was not made in cash at the time of purchase, explain in the table or in a note thereto the nature of the consideration given. If the consideration consisted of any note or other obligation, or if payment was made in installments describe the arrangement and state when the note or other obligation was discharged in full or the last installment paid.



Furnish the following information as to all securities of the issuer sold during the past 3 months by the person for whose account the securities are to be sold.

144: Securities Sold During The Past 3 Months

144: Remarks and Signature

FAQ

What does the Form 144 filed for IONS report?

The Form 144 reports a proposed sale of 10,000 Ionis common shares through Stifel Nicolaus with an aggregate market value of $503,671.

When were the shares being sold originally acquired?

The shares were acquired as Restricted Stock Units on 01/15/2019 and payment was in cash.

Has the filer sold any Ionis shares recently?

Yes. The filing discloses a sale of 10,000 shares on 08/05/2025 for $428,593.

How large is the proposed sale relative to Ionis' outstanding shares?

Ionis has 159,391,229 shares outstanding; the proposed sale of 10,000 shares is about 0.0063% of outstanding shares.

Which broker is handling the proposed sale?

The broker listed is Stifel Nicolaus & Company Inc, 501 N Broadway, St. Louis, MO 63102.
Ionis Pharmaceuticals

NASDAQ:IONS

IONS Rankings

IONS Latest News

IONS Latest SEC Filings

IONS Stock Data

12.81B
160.75M
0.65%
108.48%
6.59%
Biotechnology
Pharmaceutical Preparations
Link
United States
CARLSBAD